LongBio Pharma (Suzhou) Co., Ltd. (SEHK: 1779)
Health Care · Biotechnology · CN
HK$120.00
+0.50% today · -9.0% 1Y
LongBio Pharma (Suzhou) Co., Ltd. (SEHK: 1779) operates in the Biotechnology industry within the Health Care sector. The company is valued at $1.13B and employs 85 people.
Over the last twelve months the share price has lost 9.0%, trading between 72.65 and 165.90.
Tweenvest scores LongBio Pharma (Suzhou) Co., Ltd. across four factors: quality 26/100. Its strongest factor is quality.
1779 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.13B
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -3.10
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- HK$165.90
- 52-week low
- HK$72.65
- Avg volume (3M)
- —
- Shares outstanding
- 74.19M
- Employees
- 85
- Next earnings
- —
About LongBio Pharma (Suzhou) Co., Ltd.
Longbio Pharma (Suzhou) Co., Ltd. operates as a clinical-stage biotechnology company. It focuses on in-house discovery and development of biopharmaceuticals targeting on allergic and autoimmune diseases. The company was founded by Heng Liu and Nai-Chau Sun on October 26, 2020 and is headquartered Suzhou, China.
- ISIN
- CNE100007NF2
- Founded
- 2020
- Listed since
- Jun 5, 2026
- Exchange
- The Stock Exchange of Hong Kong Ltd.
- Currency
- HKD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $266.00 | +0.08% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $442.45 | +0.05% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.10 | -0.45% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $551.33 | -0.27% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $832.63 | -0.11% |
| argenx SEENXTBR: ARGX | $64.17B | €909.60 | +3.46% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $156.05 | -1.75% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.